Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as "Salubris") recently announced that, to further enrich its innovative product pipeline in the chronic disease field, it intends to enter into an agreement with Chengdu Sintanovo Biotechnology Co., Ltd. (hereinafter referred to as " Sintanovo ") to obtain the exclusive license rights of the intellectual property and licensed technology related to the API and formulation of STC007 (hereinafter referred to as "STC007") for all pruritus indications in the China market (i.e., mainland China, Taiwan, Hong Kong and Macau special administrative regions, same below), including but not limited to R&D, registration, manufacturing and commercialization.

STC007 is a peripheral kappa opioid receptor (KOR) agonist developed by Sintanovo. It is currently undergoing clinical studies in mainland China for the treatment of moderate-to-severe pruritus associated with abdominal surgery pain and chronic kidney disease (CKD) in adult hemodialysis patients. Among these, the Phase II clinical study for moderate-to-severe pruritus associated with CKD in adult hemodialysis patients is ongoing.

Clinical studies have shown that STC007 can activate peripheral KOR without entering the central nervous system, effectively blocking and inhibiting the transmission of pain and itch signals peripherally, thereby producing analgesic and antipruritic effects. Moreover, because STC007 does not readily cross the blood-brain barrier, it avoids the common side effects of centrally acting opioids such as respiratory depression, constipation, and addiction. Based on available preclinical and clinical data, STC007 has the potential for good efficacy and a superior safety profile.

Chronic kidney disease (CKD) is one of Salubris’ key therapeutic areas. The company has built a portfolio of multiple innovative products, including EnnaLuo®, SAL0120, SAL0140, etc. Obtaining the exclusive rights to the investigational drug STC007 (for all pruritus indications) in the China market represents a further deepening and expansion of the company’s presence in this therapeutic area. If successfully developed and approved, the drug is expected to provide patients with more comprehensive treatment strategies, expand Salubris’ innovative pipeline in chronic diseases, and enhance its core competitiveness.

|About Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd., founded in 1998, is an innovationdriven pharmaceutical company integrating R&D, production, and sales, with a foothold in China and a global vision (Stock Code: 002294). With the mission of "providing outstanding pharmaceutical products for human health," Salubris focuses on the CKM (cardiovascular-renal-metabolic) chronic disease field, primarily cardiovascular diseases. The company has launched several proprietary products, including hypertension treatments Xinchaotuo, Xinlitan, Fulitan®, and Fulian®; the renal anemia treatment EnnaLuo®; and the type 2 diabetes treatment Xinliting®.

Salubris has established five innovative drug R&D centers globally and three medical device R&D bases, forming innovation platforms covering small molecule chemical drugs, biologics, siRNA and gene editing drugs, and medical devices. The company is dedicated to addressing unmet clinical needs and improving people’s quality of life.

|About Sintanovo

Sintanovo is a wholly owned subsidiary of Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (Stock Code: 688621), focusing on innovative drug R&D and translation. The company specializes in the core area of peptides and peptide-drug conjugates, with the mission of "providing efficient R&D services to pharmaceutical companies and developing high-value innovative drugs." It has established an integrated R&D system covering the full innovation and industrial chain, creating a one-stop drug R&D service platform. Sintanovo has independently built a full suite of core technology platforms, including iCVETide® for peptide drug discovery, BiMTtide® for peptide-drug conjugate development, and PepFucina AI for peptide-based drug design. The company has provided professional technical services to nearly 100 domestic

pharmaceutical companies, and multiple innovative drug projects have entered the clinical stage. Sintanovo is recognized as a National High-Tech Enterprise and a National Intellectual Property Advantage Enterprise, holding 16 national, provincial, and municipal honors. Its R&D team is led by nationally recognized talents, with substantial achievements in patents and scientific research. Driven by technological innovation, the company aspires to become a leading domestic enterprise in peptide innovative drug R&D in the new era.